Cidara Therapeutics Stock News

Cidara Therapeutics Inc (CDTX) shares closed 3.9% lower than its previous 52 week low, giving the company a market cap of $68M. The stock is currently down 19.7% year-to-date, down 58.4% over the past 12 months, and down 89.7% over the past five years. This week, the Dow Jones Industrial Average fell 0.3%, and the S&P 500 rose 0.6%. Trading Activity Trading volume this week was 57.1% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.9. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 658.6% The company's stock price performance over the past 12 months lags the peer average by 1400.1% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Cidara Therapeutics Inc (CDTX) shares closed 2.7% lower than its previous 52 week low, giving the company a market cap of $76M. The stock is currently down 9.4% year-to-date, down 45.8% over the past 12 months, and down 89.2% over the past five years. This week, the Dow Jones Industrial Average fell 0.5%, and the S&P 500 fell 1.7%. Trading Activity Trading volume this week was 72.2% lower than the 20-day average.Beta, a measure of the stock’s volatility relative to the overall market stands at 0.8. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought.The stock closed at 11.7% lower than its 5-day moving average, 19.1% lower than its 20-day moving average, and 36.3% lower than its 90-day moving average. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 463.9% The company's stock price performance over the past 12 months lags the peer average by -973.1% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

SAN DIEGO, Jan. 06, 2022 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for pa

Compass Therapeutics (OTC:CMPX) and Cidara Therapeutics (NASDAQ:CDTX) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, earnings, profitability, institutional ownership and valuation. Insider & Institutional Ownership 47.4% of Cidara Therapeutics shares are held by institutional investors. 8.0% […]

Cidara Therapeutics (NASDAQ:CDTX) had its price target boosted by Wedbush from $5.00 to $6.00 in a research report sent to investors on Thursday, Analyst Ratings Network reports. The brokerage currently has an outperform rating on the biotechnology companys stock. A number of other research firms also recently issued reports on CDTX. HC Wainwright assumed coverage [] The post Cidara Therapeutics (NASDAQ:CDTX) Price Target Increased to $6.00 by Analysts at Wedbush appeared first on ETF Daily News .

During the last session, Cidara Therapeutics Inc. (NASDAQ:CDTX)’s traded shares were 2.04 million, with the beta value of the company hitting 1.11. At the end of the trading day, the stock’s price was $1.39, reflecting an intraday gain of 13.93% or $0.17. The 52-week high for the CDTX share is $3.15, that puts it down … Is Cidara Therapeutics Inc. (NASDAQ: CDTX) Still A Buy After sinking -14.72% Last Week? Read More »

Cidara Therapeutics Inc (NASDAQ: CDTX) and Mundipharma posted topline data from the ReSTORE Phase 3 trial of rezafungin for candidemia and invasive candidiasis. Rezafungin met the FDA primary endp

Trial met FDA and EMA-pre-specified primary endpoints versus daily standard of care Data to support global regulatory filings in mid-2022 Cidara to host investor conference call today, December 14th, at 8:30 a.m. EST to provide further details on the data SAN DIEGO and CAMBRIDGE, United Kingdom, Dec. 14, 2021 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX ) and Mundipharma today announced positive topline data from the pivotal ReSTORE Phase 3 clinical trial evaluating the efficacy and safety of its once-weekly antifungal candidate rezafungin as a potential first-line treatment for candidemia and invasive candidiasis. Rezafungin met the primary endpoint for the U.S. Food and Drug Administration (FDA) New Drug Application (NDA) submission of all-cause mortality at Day 30, and also met the primary endpoint for the European Medicines Agency (EMA) Marketing Authorization Application (MAA) submission of global cure at Day 14. Both results demonstrated statistical non-inferiority of rezafungin dosed once-weekly, versus caspofungin dosed once-daily, the current standard of care.

Millennium Management LLC grew its stake in Cidara Therapeutics, Inc. (NASDAQ:CDTX) by 810.8% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 580,793 shares of the biotechnology companys stock after purchasing an additional 517,023 shares during the period. Millennium Management LLC owned approximately []

Investors need to pay close attention to Cidara Therapeutics (CDTX) stock based on the movements in the options market lately.

Investors need to pay close attention to Cidara Therapeutics (CDTX) stock based on the movements in the options market lately.

Twist Bioscience (NASDAQ:TWST) and Cidara Therapeutics (NASDAQ:CDTX) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, risk, analyst recommendations, dividends, institutional ownership and profitability. Profitability This table compares Twist Bioscience and Cidara Therapeutics net margins, return on equity and return []

Penny stocks to watch even with Biotech ETFs heading lower today. The post 3 Biotech Penny Stocks To Watch With The Stock Market Down Today appeared first on Penny Stocks to Buy, Picks, News and Infor

Cidara Therapeutics Inc. (NASDAQ:CDTX) has a beta value of 1.10 and has seen 1.18 million shares traded in the last trading session. The company, currently valued at $100.02M, closed the last trade at $1.49 per share which meant it gained $0.06 on the day or 4.20% during that session. The CDTX stock price is -111.41% Weak Fundamental Momentum Sinks Cidara Therapeutics Inc. Read More »

Cidara Therapeutics (NASDAQ:CDTX) was downgraded by Zacks Investment Research from a hold rating to a sell rating in a report released on Tuesday, Zacks.com reports. According to Zacks, Cidara Therapeutics, Inc. is a biotechnology company. The company is focused on the discovery, development and commercialization of novel anti-infectives. Its product pipeline includes CD101 IV, a []